Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8765787 | 0.87 | POLB (0.50) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL9443701 | 0.84 | ADRB3 (0.51) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL9443665 | 0.84 | ADRB3 (0.51) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL9443694 | 0.84 | ADRB3 (0.51) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL8729260 | 0.81 | POLB (0.46) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL6108382 | 0.80 | POLB (0.51) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL4730780 | 0.78 | EPHX2 (0.44) | ALDH1A1HDAC8 | |
| SCHEMBL8768125 | 0.77 | POLB (0.40) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL8767235 | 0.77 | POLB (0.40) | POLBADRB3GAANPSR1ALDH1A1 | |
| SCHEMBL8767229 | 0.77 | POLB (0.40) | POLBADRB3GAANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | POLB 2081/4885ADRB3 3271/4885GAA 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.